A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19-Reference-Cited by-同舟云学术

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19

Published:2023-01-24 Issue:1 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kim Yeon-Sook¹,Jeon Seng-Ho²,Kim Junghee³,Koh Jong Hoon⁴,Ra Seung Won⁵,Kim Ji Won⁶,Kim Yeonjae⁷,Kim Choon Kwan⁸,Shin Yun Chul⁹,Kang Beo Deul¹⁰,Kang Seung ji¹¹,Park Chul Hee¹²,Lee Boyoung¹³,Lee Ji Yeon¹⁴,Lee Chung Hoon¹⁵,Choi Jae-phil¹⁶,Kim Jin Yong¹⁷,Yu Shi Nae¹⁸,Peck Kyong Ran¹⁹,Kim Sung-Han²⁰,Heo Jung Yeon²¹,Kim Hyun ah²²,Park Hyun-jin²³,Choi Jongwon²³,Han Jumi²³,Kim JooHyun²³,Kim Hyoung jun²³,Han Se Hee²³,Yoon Aeri²³,Park MiHee²³,Park SuJung²³,Kim YuKyung²³,Jung Minji²³^ORCID,Oh Myoung-don²⁴^ORCID

Affiliation:

1. Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea

2. Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea

3. Department of Neurosurgery, Seoul Medical Center, Seoul, South Korea

4. Department of Internal Medicine, Seonam Hospital, Seoul, South Korea

5. Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea

6. Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea

7. Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul, South Korea

8. Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, South Korea

9. Department of Anesthesiology and Pain Medicine, Gyeonggi Provincial Medical Center Pocheon Hospital, Pocheon, South Korea

10. Department of Internal Medicine, Gyeonggi Provincial Medical Center Ansung Hospital, Ansung, South Korea

11. Department of Internal Medicine, Chonmam National University Medical School, Gwangju, South Korea

12. Department of Internal Medicine, Gyeonggi Provincial Medical Center Icheon Hospital, Icheon, South Korea

13. Department of Internal Medicine, Gyeonggi Provincial Medical Center Uljeongbu Hospital, Uljeongbu, South Korea

14. Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, South Korea

15. Department of Obstetrics and Gynecology, Gyeonggi Provincial Medical Center Suwon Hospital, Suwon, South Korea

16. Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea

17. Department of Internal Medicine, Incheon Medical Center, Incheon, South Korea

18. Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea

19. Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

20. Department of Internal Medicine, Asan Medical Center, Seoul, South Korea

21. Department of Infectious Diseases, Ajou University School of Medicine, Suwon, South Korea

22. Department of Medicine, Division of Infectious Diseases, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea

23. Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea

24. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Abstract

Although several antiviral agents have become available for coronavirus disease 2019 (COVID-19) treatment, oral drugs are still limited. Camostat mesylate, an orally bioavailable serine protease inhibitor, has been used to treat chronic pancreatitis in South Korea, and it has an in vitro inhibitory potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00452-22

Reference22 articles.

1. World Health Organization. 2022. Weekly epidemiological update on COVID-19. WHO Geneva Switzerland. https://www.who.int/publications/m/item/weekly-epidemiological-update---2-march-2021. Accessed 8 February 2022.

2. Dexamethasone in Hospitalized Patients with Covid-19

3. Remdesivir for the Treatment of Covid-19 — Preliminary Report

4. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

5. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TMPRSS2-specific antisense oligonucleotides inhibit host cell entry of emerging viruses;Virology;2024-12

2. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery;Expert Opinion on Drug Discovery;2024-07-30

3. Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials;BMC Infectious Diseases;2024-07-19

4. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate;Clinical Microbiology and Infection;2024-06

5. Individual Patient Data Meta-Analysis evaluating Camostat Mesilate to Treat COVID-19 in Community Settings;2024-05-17